Therapeutic Focus: What Tavalisse Treats and What Benefit It Provides

Tavalisse is commonly used to help manage chronic immune thrombocytopenia (ITP) in adult patients whose condition is characterized by symptoms related to systemic imbalance that may intensify temporarily. The medication is applied when appropriate if a prior treatment for the low platelet count has not worked well enough, making it highly relevant for conditions involving episodic or fluctuating manifestations (Refractory ITP).

Management of Chronic, Refractory Immune Thrombocytopenia

This treatment is applied across domains where additional symptomatic support is needed for chronic ITP, particularly when the low platelet count remains unresponsive to previous therapeutic approaches. The treatment is used for managing conditions marked by low platelet counts (thrombocytopenia) associated with an increased risk of bleeding, assisting with easing the risk of excessive bleeding, and is relevant for easing visible manifestations like easy bruising and spontaneous mucosal bleeding.

Improvement in Quality of Life and Functional Stability

Achieving a sustained platelet response may help maintain a sense of stability when symptoms are more noticeable, which contributes to improved comfort for patients dealing with chronic, symptomatic ITP. By helping to maintain platelet counts above protective thresholds, Tavalisse contributes to easing the overall symptom load and assists with maintaining functional stability, thereby supporting the patient during difficult episodes by easing distress.

---

Quick Fact: Supportive management for bleeding risk

---

Regulatory References

1. Fostamatinib NIH MedlinePlus overview

Tavalisse (fostamatinib) is approved for use only within a specific patient population as defined by regulatory bodies like the FDA and EMA. The medication is indicated only for adult patients (aged 18 years and older) who have chronic immune thrombocytopenia (ITP) that is refractory to a previous treatment.

Who Must Not Use Tavalisse

Population	Regulatory Status
Pregnant Women	Contraindicated
Known Hypersensitivity	Contraindicated
Children/Adolescents (<18)	Not Recommended
Severe Hepatic Impairment	Should Not Be Used

Conditional and Restricted Use

Use of Tavalisse requires specific precautions for certain groups:

• Females of Reproductive Potential must use effective contraception during treatment and for at least one month after the final dose.
• Lactating Women must discontinue breastfeeding during treatment and for one month following the last dose.
• Patients with mild or moderate hepatic impairment are permitted to use the medicine but require mandated liver function monitoring throughout therapy.
• Renal Impairment and Geriatric Patients do not require a dose adjustment, indicating established eligibility for these populations.

Tavalisse (fostamatinib) has documented interactions with several categories of medicinal products, primarily involving the drug-metabolizing enzyme CYP3A4 and drug transporters. The active metabolite of Tavalisse, R406, is central to these interactions.

Impact on Tavalisse Levels

• Strong CYP3A4 Inhibitors: Concomitant use with strong inhibitors of CYP3A4 increases the exposure of R406, which may elevate the risk of adverse reactions. This necessitates monitoring for toxicities and potential modification of the Tavalisse dosage.
• Strong CYP3A4 Inducers: Concomitant use with strong CYP3A4 inducers is not recommended. These agents reduce the exposure to R406, which can potentially diminish Tavalisse's effect.

Impact on Other Medicines

• CYP3A4 Substrates: Tavalisse may increase the concentrations of coadministered drugs that are substrates of CYP3A4, requiring dose reduction of the substrate drug.
• Transporter Substrates (P-gp/BCRP): Tavalisse inhibits the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Coadministration may increase the concentration of P-gp substrate drugs (e.g., digoxin) and BCRP substrate drugs (e.g., rosuvastatin), potentially requiring dosage reduction of the coadministered drug.

Contraindicated Combinations

• Use with certain sensitive CYP3A4 substrate drugs, such as Lonafarnib, is contraindicated due to the significant risk of increased exposure and adverse effects from the coadministered drug.

The mechanism of action involves the targeted, dual modulation of immune cell signaling and alters the dynamics of platelet regulation. The active form, R406, acts as a selective competitive inhibitor of the enzyme Spleen Tyrosine Kinase (SYK). SYK is crucial for propagating signals from immune receptors, particularly Fc Receptors on macrophages and the B-cell Receptor (BCR). By binding to the ATP pocket of SYK, R406 blocks the initial signaling cascade, disrupting downstream pathways like PI3K/Akt and NF-kappaB that drive immune cell function.

This action provides a dual physiological effect: blockade of Fc Receptor-mediated signaling prevents macrophage-driven platelet destruction (reduced clearance). Simultaneously, the inhibition of SYK signaling is also associated with influencing megakaryocyte survival and maturation in the bone marrow (enhanced production). This combined action results in the modulation of the circulating platelet level set point. The functional mechanism requires the involvement of SYK in the destructive pathway but does not significantly affect SYK-independent signaling pathways. Additionally, R406 exhibits minor off-target activity against molecules like the Adenosine A3 receptor, which can modulate non-primary physiological functions.

Tavalisse (fostamatinib) is administered orally as a film-coated tablet in either 100 mg or 150 mg strengths. The general principle of its use involves a continuous, twice-daily schedule that must be initiated and overseen by a physician specializing in hematological diseases.

The standard treatment protocol is structured with a defined starting dose and a set timeframe for evaluation. The initial dose is 100 mg taken twice daily. If the platelet response is deemed insufficient after four weeks, the dose may be increased to the maximum recommended daily dose of 300 mg, administered as 150 mg twice daily.

Administration is flexible regarding meals, as the tablets may be taken with or without food, but they must always be swallowed whole. Guidelines provide clear instruction for deviations: if a dose is missed, the patient should skip that dose and take the next scheduled dose at the regular time. Dose adjustments are generally not necessary for older adults or those with renal impairment, but the use of the medicine is not recommended in patients with severe hepatic impairment.

Furthermore, the protocol mandates that treatment must be discontinued after 12 weeks of therapy at the maximum dose if the platelet count remains insufficient to prevent clinically important bleeding.

Research Evidence / Overview of Studies for Tavalisse

This section provides a factual overview of the clinical research and study structures that support the use of Tavalisse (fostamatinib). It strictly outlines what research was evaluated for patients with chronic immune thrombocytopenia (ITP) and describes the known limitations and uncertainties in the current evidence landscape.

---

Evidence for use in Chronic ITP Unresponsive to Previous Treatment

The primary research reviewed by regulators consisted of two identical, short-term (24-week), placebo-controlled, randomized clinical trials (known as FIT-1 and FIT-2). These studies were conducted to evaluate whether the medicine could impact low platelet counts in adult patients with chronic ITP whose condition did not adequately respond to at least one previous therapeutic approach.

Research examined the main goal of treatment by monitoring the Stable Platelet Response. The combined trial data report measurements of this Stable Platelet Response in a portion of patients who received the study drug, a pattern that was not consistently observed in the placebo groups. Studies also explored outcomes related to the frequency of bleeding episodes and the use of rescue medication.

Durability of Response and Long-Term Research

Long-term follow-up data was collected through an Open-Label Extension Study (FIT-3), allowing researchers to explore what was observed in a non-controlled, extended timeframe. Studies explored the durability of the observed responses over several years. Available data from this extended research describes patterns where, for patients who continued receiving the study drug, a pattern of stable platelet counts was observed for an extended duration, sometimes for over two years.

Limitations and Research Gaps

The evidence base was studied for chronic ITP through Phase 3 Trials, but several limitations exist in the current research body. A key structural limitation is the short duration of the controlled, double-blind trials, which spanned only 24 weeks. This means that long-term effects are not fully established based on the available controlled data.

Comparative evidence is lacking from trials that directly tested Tavalisse against other available second-line treatments. Furthermore, research was studied for adult patients only, meaning data for certain groups (e.g., children with chronic ITP) remain insufficient and is not available.

Common questions about Tavalisse (FAQ)

Q: How quickly should I expect to see improvement after starting Tavalisse?

A: Studies indicate that the platelet response is evaluated after four weeks of treatment at the starting dose before any potential dose adjustments are considered. Regulatory research often uses the 12-week mark to assess whether a sufficient platelet response has been observed.

Q: What are the most common side effects people report when taking Tavalisse?

A: According to official product information, the most commonly reported side effects in clinical trials include gastrointestinal issues such as diarrhea, nausea, and abdominal pain. Other common effects include hypertension (high blood pressure) and fatigue.

Q: Does Tavalisse affect my liver or kidney function?

A: Regulatory information indicates that Tavalisse can cause elevations in liver function tests. It is contraindicated for use in patients with severe hepatic impairment (severe liver problems). For patients with kidney impairment, a dose change is not generally required. However, liver function tests are typically monitored throughout therapy due to potential changes.

Q: Are there any foods or drinks I need to avoid while on Tavalisse?

A: The official product information states that Tavalisse has no specific food restrictions and can be taken with or without food. Patients are always encouraged to follow the guidance provided by their healthcare team.

Q: How does Tavalisse work differently from other ITP medications?

A: Tavalisse is considered a first-in-class Spleen Tyrosine Kinase (SYK) inhibitor. This means it works by targeting a specific enzyme, SYK, to block the destruction of platelets. The current research base includes data from placebo-controlled trials, but formal comparative data against all other available ITP treatments are limited.

Q: Will Tavalisse cure my ITP, or is it a long-term treatment?

A: Tavalisse is an approved treatment for chronic ITP intended to help raise and maintain platelet counts. It is not described as a cure. Clinical research, including long-term follow-up studies, has explored its use over extended periods, with some patients maintaining stable platelet counts for over two years.

Q: What is the longest period someone has safely taken Tavalisse?

A: Data from the open-label extension study (FIT-3) included patients who continued receiving the medicine for extended durations. This research noted patterns of stable platelet counts observed for over two years.

Q: What are the signs of a serious reaction to Tavalisse that require immediate attention?

A: Serious adverse reactions officially documented include signs of very high blood pressure (hypertensive crisis), fever with low white blood cell count (febrile neutropenia), and severe diarrhea. Patients are advised to monitor for symptoms such as severe headaches, chest pain, difficulty breathing, yellowing of the skin or eyes, or high fever.

Q: What kind of infections should I be watching out for while on Tavalisse?

A: The medicine can cause a drop in white blood cells, called neutropenia, which increases the risk of infection. Official safety data has specifically documented respiratory infection and pneumonia as adverse reactions. Patients are encouraged to monitor for general signs of infection like fever or a persistent sore throat, especially due to the potential for neutropenia.

Q: Does Tavalisse affect fertility in men or women?

A: Official information states that the medicine may affect female fertility. It is formally contraindicated during pregnancy, and females of reproductive potential must use effective contraception during treatment and for a specified time after the last dose.

Q: How does Tavalisse impact the spleen?

A: Tavalisse works by inhibiting the Spleen Tyrosine Kinase (SYK) enzyme. SYK is a key component in the cellular process that leads to platelet destruction, a process often associated with the spleen. By blocking SYK, the medicine helps to reduce this destruction.

Q: Is there a generic version of Tavalisse available?

A: Tavalisse is currently sold as a brand-name medication. The medicine is currently available only under its brand name. Information on the availability of a generic version is governed by regulatory and patent law.

Q: Does Tavalisse affect my ability to drive or operate machinery?

A: Tavalisse can cause side effects such as dizziness and fatigue. Official safety documentation advises that these effects could impair the ability to drive or operate machinery. Caution is advised for patients until they are aware of how the medicine affects them.

Q: Does Tavalisse interact with common blood pressure or diabetes medications?

A: Tavalisse can change the concentration of drugs that are broken down by the CYP3A4 enzyme or transported by P-glycoprotein. Since certain blood pressure and diabetes medicines use these pathways, dose adjustments for those medications may be required.

Q: Can Tavalisse cause hair loss or weight gain?

A: Neither hair loss nor weight gain are listed among the most common adverse reactions in the official regulatory documents.

Q: Can I take over-the-counter pain relievers like ibuprofen with Tavalisse?

A: The official product labeling is centered on specific prescription drug interactions and warnings about liver problems. It does not explicitly state whether common OTC pain relievers are safe. Patients should discuss all over-the-counter products with their healthcare provider.

Q: What should I do if I experience dizziness or fatigue after starting Tavalisse?

A: Dizziness and fatigue are common adverse reactions noted in official safety information. If these effects become severe, they may require the healthcare provider to interrupt, reduce the dose of, or discontinue Tavalisse. Patients are advised to report these symptoms to a healthcare professional.

Q: Is it normal to feel a bit nauseous when first starting Tavalisse?

A: Yes, nausea is listed in regulatory documents as one of the most common adverse reactions reported during clinical trials. It is a known effect that may be experienced when treatment is first initiated.

Q: Can I take supplements or vitamins while on Tavalisse?

A: The active ingredient in Tavalisse is sensitive to drug-metabolizing enzymes like CYP3A4. Since some supplements and vitamins can interfere with these pathways, patients are advised to review all concurrent use with a healthcare professional.

Q: Does Tavalisse interact with herbal remedies like St. John's Wort?

A: Yes, St. John's Wort is classified as a strong CYP3A4 inducer. Official product information states that strong CYP3A4 inducers are not recommended for use with Tavalisse because they can reduce the concentration of the active medicine, potentially diminishing its effect.

Q: How effective is Tavalisse in children or adolescents?

A: Tavalisse is only indicated for adult patients. Use in children and adolescents under 18 years is not recommended due to safety findings related to actively growing bones. There are no clinical trial data available for this age group.

Q: Why does my doctor need to check my blood count so frequently while taking Tavalisse?

A: Frequent monitoring of blood counts is mandated to check two things: to assess the platelet response to the medicine, and to watch for a serious drop in white blood cells, called neutropenia. Neutropenia is an adverse reaction that requires management.

Q: What is the cost of Tavalisse without insurance?

A: Official health economic reviews state that Tavalisse has a high annual cost per patient. Financial support or coverage should be discussed directly with an insurer or healthcare provider.

How to Store and Dispose of TAVALISSE

Official regulatory information requires TAVALISSE (fostamatinib) tablets to be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C to 30 C (59 F to 86 F). The medicine must be kept protected from moisture.

Container and Disposal Rules

Tablets must be stored in the original bottle and kept tightly closed. The bottle's two desiccant canisters must not be removed. Any unused TAVALISSE tablets must be discarded 60 days after opening the bottle.

As a mandatory storage requirement, the product must be kept out of the sight and reach of children.

Disposal of unused medicine or waste material must be done in accordance with local requirements. Medicines should not be thrown away via wastewater or household waste.